January 21, 2021
Business News

Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition

BOSTON–()–Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral presentation the updated and expanded results from a Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held virtually December 5–8.

GDA-201 was well-tolerated and no dose-limiting toxicities were observed in 35 patients (19 with NHL and 16 with MM). The data show that therapy using GDA-201 with…

Click here to view the original article.

Related Posts

You might also like ...

Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences
Crowdsourced Security on the Rise: YesWeHack Announces Record Growth in Asia
DECT Forum: DECT Award 2021 Registration Open